Ubiquitin‐specific protease 22 controls melanoma metastasis and vulnerability to ferroptosis through targeting SIRT1/PTEN/PI3K signaling
MedComm · 2024-08 · 5 (8)
DOI: 10.1002/mco2.684 ↗At a glance
Journal article in MedComm, published online on 2024-08-12. Written by Huiyan Sun and 13 co-authors. Institution: Department of Dermatology Xiangya Hospital Central South University Changsha China. Cited 23 times so far (Crossref); 55 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Huxiang Youth Talent Support Program, Natural Science Foundation of Hunan Province.
Abstract (original language)
Metastasis is a major contributing factor that affects the prognosis of melanoma patients. Nevertheless, the underlying molecular mechanisms involved in melanoma metastasis are not yet entirely understood. Here, we identified ubiquitin‐specific protease 22 (USP22) as a pro‐oncogenic protein in melanoma through screening the survival profiles of 52 ubiquitin‐specific proteases (USPs). USP22 demonstrates a strong association with poor clinical outcomes and is significantly overexpressed in melanoma. Ablation of USP22 expression remarkably attenuates melanoma migration, invasion, and epithelial–mesenchymal transition in vitro and suppresses melanoma metastasis in vivo. Mechanistically, USP22 controls melanoma metastasis through the SIRT1/PTEN/PI3K pathway. In addition, we conducted an United States Food and Drug Administration‐approved drug library screening and identified topotecan as a clinically applicable USP22‐targeting molecule by promoting proteasomal degradation of USP22. Finally, we found that both pharmacological and genetic silence of USP22 sensitize RSL3‐induced ferroptosis through suppressing the PI3K/Akt/mTOR pathway and its downstream SCD, and ferroptosis inhibitor could partly rescued the decreased lung metastasis by topotecan in vivo. Overall, our findings reveal a prometastatic role of USP22 and identify topotecan as a potent USP22‐targeting drug to limit melanoma metastasis.
Subjects
Author keywords
Authors and institutions
- Department of Dermatology Xiangya Hospital Central South University Changsha China.
- National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology Changsha China.
- Furong Laboratory Changsha China.
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital Central South University Changsha China.
- National Clinical Research Center for Geriatric Disorders (Xiangya Hospital) Changsha China.
- Department of Breast Reconstruction Tianjin Medical University Cancer Institute and Hospital Tianjin China.
ORCID profiles: Guangtong Deng, Furong Zeng
Funding
- National Natural Science Foundation of China
- Huxiang Youth Talent Support Program
- Natural Science Foundation of Hunan Province
Cite
APA
Sun, H., Meng, Y., Yao, L., Du, S., Li, Y., Zhou, Q., Liu, Y., Dian, Y., Sun, Y., Wang, X., Liang, X. W., Deng, G., Chen, X., & Zeng, F. (2024). Ubiquitin‐specific protease 22 controls melanoma metastasis and vulnerability to ferroptosis through targeting SIRT1/PTEN/PI3K signaling. MedComm, 5(8). https://doi.org/10.1002/mco2.684
Vancouver
Sun H, Meng Y, Yao L, Du S, Li Y, Zhou Q, et al. Ubiquitin‐specific protease 22 controls melanoma metastasis and vulnerability to ferroptosis through targeting SIRT1/PTEN/PI3K signaling. MedComm. 2024;5(8). doi:10.1002/mco2.684
BibTeX
@article{Sun2024,
author = {Sun, Huiyan and Meng, Yu and Yao, Lei and Du, Songtao and Li, Yayun and Zhou, Qian and Liu, Yihuang and Dian, Yating and Sun, Yuming and Wang, Xiaomin and Liang, Xiao-Wei and Deng, Guangtong and Chen, Xiang and Zeng, Furong},
title = {Ubiquitin‐specific protease 22 controls melanoma metastasis and vulnerability to ferroptosis through targeting SIRT1/PTEN/PI3K signaling},
journal = {MedComm},
year = {2024},
volume = {5},
number = {8},
doi = {10.1002/mco2.684}
}
EUVIMED